Peter Zerhouni
Peter Zerhouni
Chief Executive Officer (CEO) since 2015. Chairman of the board of InDex Pharmaceuticals AB and InDex Diagnostics AB.
Read more
Peter Zerhouni
Peter Zerhouni
Chief Executive Officer (CEO) since 2015. Chairman of the board of InDex Pharmaceuticals AB and InDex Diagnostics AB.

Born: 1972.

Other current assignments: –

Experience: Zerhouni has extensive experience in developing life science companies from both a scientific and commercial perspective. Peter joined InDex from the listed company Diamyd Medical AB where he was CEO since 2011 and where he also has been head of business development. He was a driving force behind one of the largest biotech out-licensing deals in Sweden in 2010. Zerhouni has previously held various positions at ING Bank in Brussels and Amsterdam. He holds a Master of Science degree in Biology as well as a Bachelor of Science degree in Business Administration and Economics from Lund University (part of the course work was completed at University of California at Berkeley).

Shareholding in InDex: Direct holding of 660 000 shares and 333 333 warrants.

Johan Giléus
Johan Giléus
Chief Financial Officer (CFO) since 2017. Board member of InDex Pharmaceuticals AB and InDex Diagnostics AB.
Read more
Johan Giléus
Johan Giléus
Chief Financial Officer (CFO) since 2017. Board member of InDex Pharmaceuticals AB and InDex Diagnostics AB.

Born: 1965.

Other current assignments: Giléus is a member of the board and CEO of Giléus Consulting AB and Giléus Invest AB and a member of the board and chairman of the audit committee of BHG Group AB. Giléus is also partner of Professionell ägarstyrning i Sverige AB.

Experience: Giléus is also engaged as an independent financial advisor with M&A, external financial reporting and other stock market issues. He has broad experience from sectors like Life Science, Energy, Services and Manufacturing. During the last 25 years Giléus has worked with Swedish and international strategic and financial clients in acquisitions and divestments. Giléus was until May 2015 partner at Deloitte AB with a focus on M&A and stock market issues. Giléus was also on the board of Deloitte AB up until 2014.He has also been involved in some 75 IPOs. Giléus has studied business administration at Stockholm University.

Shareholding in InDex: Direct holding of 240 000 shares and 133 333 warrants.

Dr. Thomas Knittel
Dr. Thomas Knittel
Chief Medical Officer (CMO) since 2012
Read more
Dr. Thomas Knittel
Dr. Thomas Knittel
Chief Medical Officer (CMO) since 2012

Born: 1962.

Other current assignments: Knittel is board member of Heparegenix.

Experience: Knittel has over 15 years of clinical experience within medical gastroenterology as well as 13 years of experience in medical affairs and marketing management. Before joining InDex Pharmaceuticals, he held positions as Business Unit Director and Director of Sales and Marketing at Novo Nordisk A/S for central Europe, as General Manager Pharmaceuticals at Harlan Laboratories Ltd, and as Vice President Corporate and Medical Affairs at Develogen AG. He has a Medical degree from the University of Mains with a specialist training in internal medicine and gastroenterology. He is an Associate Professor in Internal Medicine and Gastroenterology at the University Clinic Goettingen. In addition, he has an MBA from Kellogg School of Management/WHU.

Shareholding in InDex: Direct holding of 10 000 shares and 66 667 warrants.

Pernilla Sandwall
Pernilla Sandwall
Chief Operating Officer (COO) since 2012. Board member of InDex Pharmaceuticals AB and InDex Diagnostics AB.
Read more
Pernilla Sandwall
Pernilla Sandwall
Chief Operating Officer (COO) since 2012. Board member of InDex Pharmaceuticals AB and InDex Diagnostics AB.

Born: 1963.

Other current assignments: Sandwall is a board member of Alzinova AB och Innovativa Mindre Life science företag (IML, which is a part of the trade association Läkemedelsindustriföreningen).

Experience: Sandwall has worked at Merck & Co. Inc./MSD for more than 20 years, both in the Swedish subsidiary and the headquarters in US, with the clinical operations organization. She has experience in the field as CRA and project manager, as well as strategically as Clinical Research Manager. Her focus over the last years has been global patient recruitment, site selection strategies and execution. She also has experience in change management and Lean Six Sigma methodology. She holds a Master of Science in Pharmacy from Uppsala University.

Shareholding in InDex: Direct holding of 130 000 shares and 133 333 warrants.